



Immunology and Vaccines Development on HIV, Measles, Chikungunya Virus and SARS-CoV-2

Guest Editors:

Dr. Anil Kumar Verma

Center for Immunology and Infectious Diseases, University of California Davis, 1 Shield Ave, Davis, CA 95616, USA

Dr. Kaustuv Nayak

ICGEB-Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067, India

Deadline for manuscript submissions:
closed (30 August 2023)

Message from the Guest Editors

As commonly reported, HIV, measles, chikungunya virus, and SARS-CoV2 are global health issues. Recurrent productive infections are responsible for high morbidity and mortality. The induction of antigen/viral-specific immune responses plays an evident role in the development of a durable and effective vaccine. However, there is still an incomplete understanding of the immune response of pathways elicited by viral infections, fill gaps by the rational design of prophylactic and/or therapeutic vaccines, and the choice of the proper adjuvant to elicit protective response.

To achieve a more extensive understanding of recent scientific knowledge and current trends in viral vaccine development, this Special Issue focuses on the recent scientific and progresses made in this field. Based on your extensive knowledge and experience, we invite you to contribute an original report, original observation, or review to highlight (i) antibody protection, (ii) immune responses after primary/secondary infection, and (iii) recent advances in the development of novel prophylactic and therapeutic vaccines.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)